Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Overview of attention for article published in Clinical Cancer Research, August 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

news: 1 news outlet

twitter: 7 X users

Readers on

mendeley: 20 Mendeley

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 12,704 followers.

RT @TeamOvary_MSK: Take a look at the new analysis of molecular results and potential biomarkers from the MILO/ENGOT-ov11 study for recurre…

Take a look at the new analysis of molecular results and potential biomarkers from the MILO/ENGOT-ov11 study for recurrent low-grade serous ovarian cancer. https://t.co/aMpBqXQh8d #TeamOvary_MSK #rachelgrishamMD

RT @DrLB: Molecular analysis from the Phase III MILO/ENGOT-ov11 Study of Binimetinib shows that Somatic tumor testing should be routinely c…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.